RUIXIAO LU, PH.D.

ALUMIS

Ruixiao Lu, Ph.D. is a statistical leader in the biotech/biopharma industry with a particular interest in targeted therapies and personalized patient management. Currently, she is VP, Head of Biostatistics & Statistical Programming, at Alumis Inc, a precision medicine company focusing on autoimmune diseases. Before Alumis, she was VP, Head of Statistics, Clinical Data Management & Data Science overseeing the statistics and analytical teams, at Quantum Leap Healthcare, the trial sponsor of the I-SPY2 trial and I-SPY COVID trial, which are among the first platform trials in Oncology and COVID clinical research. Before then, she worked at Genomic Health/Exact Sciences, with increasing responsibilities leading product development and medical affairs programs, and in the end as the Director and functional head for the statistics and programming. She also contributed to business development evaluation and provided strategic input to product lifecycle management throughout her career.

Besides her day job, Ruixiao is dedicated to promoting statistics and data sciences with various non-profit organizations including ASA, BBSW and DahShu. At BBSW, she was a founding member and currently Secretary to the Board. At DahShu, she was a founding member and currently a Board member. At the ASA, she is currently the Treasurer and Executive Committee Member of the Board of ASA, was elected Vice Chair of District 6, COCGB at ASA, and past San Francisco Bay Area chapter President.

Ruixiao is devoted in promoting cross-disciplinary partnership, especially between the medical community and statistical/quantitative science community. She co-founded and chairs the special interest group at ASA, Partnership for Clinical Research and Statistics (PCRS), which focuses on building partnerships and programs with the FDA and various professional non-profit organizations such as AACR and ASCO.